A Comparison of Prothrombin Complex Concentrate and Recombinant Activated Factor VII for the Management of Bleeding With Cardiac Surgery
- PMID: 33402016
- DOI: 10.1177/0885066620984443
A Comparison of Prothrombin Complex Concentrate and Recombinant Activated Factor VII for the Management of Bleeding With Cardiac Surgery
Abstract
Bleeding following cardiac surgery that warrants transfusion of blood products is associated with significant complications, including increased mortality at 1 year following surgery. Factor concentrates, such as prothrombin complex concentrate (PCC), or recombinant activated factor VII (rFVIIa) have been used off-label for bleeding in cardiac surgery that is refractory to conventional therapy. The objective of this retrospective study is to assess the hemostatic effectiveness of 4-factor PCC or rFVIIa for bleeding after a broad range of cardiac surgeries. Patients were included if they were at least 18 years of age and had undergone cardiac surgery with bleeding requiring intervention with 4-factor PCC or rFVIIa. There were no differences observed in the number of packed red blood cells (4-factor PCC: 2 units vs. rFVIIa: 2 units), fresh frozen plasma (0 units vs. 1 unit) or platelet (2 units vs. 2 units) transfusions following the administration of 4-factor PCC or rFVIIa. The patients in the rFVIIa group, required more cryoprecipitate than those in the 4-factor PCC group (4-factor PCC: 2 units (range 0-6) vs. rFVIIa: 2 units (range 0-8), p = 0.03). There were no differences in secondary outcomes of chest tube output at 2, 6, 12 and 24 hours, nor was there a difference in reexploration rates or the median length of stay in the intensive care unit. Thromboembolic complications at 30 days were similar between the two groups (4-factor PCC: 13% vs. rFVIIa 26%, p = 0.08). The total median dose requirement for 4-factor PCC was 1000 units (15 units/kg) and 2 mg (20 mcg/kg) for rFVIIa. The results demonstrate feasibility of utilizing the minimum amount of drug in order to achieve a desired effect. Both 4-factor PCC and rFVIIa appear to be safe and effective options for the management of bleeding associated with cardiac surgery.
Keywords: bleeding; cardiac surgery; critical care; safety.
Similar articles
-
Activated Factor 7 Versus 4-Factor Prothrombin Complex Concentrate for Critical Bleeding Post-Cardiac Surgery.Ann Pharmacother. 2018 Jun;52(6):533-537. doi: 10.1177/1060028017752365. Epub 2018 Jan 13. Ann Pharmacother. 2018. PMID: 29332420
-
Comparison of Low Dose Recombinant Factor VIIa and 4-Factor Prothrombin Complex Concentrate for Treatment of Bleeding Related to Cardiac Surgery.J Pharm Pract. 2024 Oct;37(5):1149-1156. doi: 10.1177/08971900241228766. Epub 2024 Jan 23. J Pharm Pract. 2024. PMID: 38261533
-
Outcomes Following Three-Factor Inactive Prothrombin Complex Concentrate Versus Recombinant Activated Factor VII Administration During Cardiac Surgery.J Cardiothorac Vasc Anesth. 2018 Feb;32(1):151-157. doi: 10.1053/j.jvca.2017.07.011. Epub 2017 Jul 12. J Cardiothorac Vasc Anesth. 2018. PMID: 29217234
-
Race against the clock: overcoming challenges in the management of anticoagulant-associated intracerebral hemorrhage.J Neurosurg. 2014 Aug;121 Suppl:1-20. doi: 10.3171/2014.8.paradigm. J Neurosurg. 2014. PMID: 25081496 Review.
-
Is recombinant activated factor VII effective in the treatment of excessive bleeding after paediatric cardiac surgery?Interact Cardiovasc Thorac Surg. 2012 Oct;15(4):690-4. doi: 10.1093/icvts/ivs309. Epub 2012 Jul 18. Interact Cardiovasc Thorac Surg. 2012. PMID: 22811512 Free PMC article. Review.
Cited by
-
Analysis of the effect of initial hemostasis resuscitation with recombinant human coagulation factor VII a on the treatment of postoperative hemorrhage in cardiac surgery.J Cardiothorac Surg. 2025 Jan 4;20(1):13. doi: 10.1186/s13019-024-03278-6. J Cardiothorac Surg. 2025. PMID: 39755651 Free PMC article.
-
Optimal management of cardiac surgery patients using direct oral anticoagulants: recommendations for clinical practice.Eur J Cardiothorac Surg. 2023 Oct 4;64(4):ezad340. doi: 10.1093/ejcts/ezad340. Eur J Cardiothorac Surg. 2023. PMID: 37812245 Free PMC article.
-
Prothrombin Complex Concentrate vs Factor VII for Refractory Bleeding in Cardiac Surgery.Ann Thorac Surg Short Rep. 2023 Jul 12;1(4):691-695. doi: 10.1016/j.atssr.2023.06.006. eCollection 2023 Dec. Ann Thorac Surg Short Rep. 2023. PMID: 39790662 Free PMC article.
-
Prothrombin complex concentrate in cardiac surgery for the treatment of coagulopathic bleeding.Cochrane Database Syst Rev. 2022 Nov 21;11(11):CD013551. doi: 10.1002/14651858.CD013551.pub2. Cochrane Database Syst Rev. 2022. PMID: 36408876 Free PMC article.
-
Hemostasis Using Prothrombin Complex Concentrate in Patients Undergoing Cardiac Surgery: Systematic Review with Meta-Analysis.Braz J Cardiovasc Surg. 2024 Apr 3;39(2):e20230076. doi: 10.21470/1678-9741-2023-0076. Braz J Cardiovasc Surg. 2024. PMID: 38568885 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical